GI ASCO 2015, San Francisco

Discussion Board Forums Announcements GI ASCO 2015, San Francisco

Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
    Posts
  • #86380
    dukenukem
    Member

    My FoundationOne results showed hits on IDH1 and CDKN2A/B loss which show up in this abstract. One did not, NRAS.

    Dr. Javle, Foundation Medicine, and MDA were among the names I recognized as contributors.

    Duke

    #10897
    marions
    Moderator

    Reporting back (a bit late) from GI ASCO 2015.

    Abstract:Tumor profiling for distinct molecular alterations.

    Focused on IDH 1 and IDH 2 which are metabolic enzymes found in several malignancies. These enzymes help break down nutrients and generate the energy for cells. However; once mutated, IDH creates molecules which interfere with the genetic profiling; cells don’t mature but rather they multiply rapidly ultimately leading to malignant tumors.

    Another study demonstrated that extrahepatic CCA had the highest rate of KRAS mutation whereas intrahpetic CC which showed evidence of the highest rate of IDH -1 mutations.

    HER2 mutations were higher in extrahepatic CCA than in intrahepatic CCA suggesting that HER2 targeted therapy may prove positive for this subgroup of patients.

    It also is suggested that further studies may prove that intrahepatic CCA may identify additional molecular subgroups.

    With continued profiling studies, we will gain a better insight into the disease biology which then should lead to sensitivity identification for distinct therapies.

    The below abstract on genomic profiling of biliary cancers showed responses to drugs on the market or drugs under evaluation in clinical trials.
    Note: IHCCA (intrahepatic) EHCCA (extrahepatic) GBCA (gallbladder)

    http://meetinglibrary.asco.org/content/139827-158

    Hugs to all,
    Marion

Viewing 2 posts - 1 through 2 (of 2 total)
  • The forum ‘Announcements’ is closed to new topics and replies.